Scientia, Dipòsit d’Informació Digital del Departament de Salut
Not a member yet
12576 research outputs found
Sort by
Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review
Get PDFFabry disease; Agalsidase alfa; EffectivenessEnfermedad de Fabry; Agalsidasa alfa; EfectividadMalaltia de Fabry; Agalsidasa alfa; EfectivitatObjectives: This systematic literature review aimed to identify studies assessing the clinical efficacy and real-world effectiveness of current and emerging treatments for Fabry disease. Methods: Searches of the MEDLINE, EMBASE, and Cochrane library databases, as well as relevant congress proceedings, were conducted to identify publications reporting on studies in patients of any age, sex, race, or ethnicity who received any approved or experimental treatment for Fabry disease, published before 17 June 2024. Results: Of 1881 publications screened, 234 reported data on renal, cardiac, cerebrovascular, and disease severity outcomes from 225 studies. The majority of reported studies were observational in nature (n = 150; 67%) and involved only adults (n = 172; 74%). Study designs and patient populations were highly heterogeneous, and cross-study conclusions about the effectiveness of different therapies could not be made. Enzyme replacement therapy (ERT) with agalsidase alfa or agalsidase beta stabilized renal function and cardiac structure in patients with Fabry disease. Early initiation of ERT in childhood or young adulthood was associated with better renal and cardiac outcomes than treatment initiation at a later age. The small number of comparator studies of agalsidase alfa and agalsidase beta suggested similar efficacy. Patients treated with migalastat and pegunigalsidase alfa also maintained stable renal function and cardiac structure. Conclusions: Overall, current treatments slow the progression of renal and cardiac decline in patients with Fabry disease. Large cohort studies with long-term follow-up and baseline stratification based on clinical phenotype are needed to address evidence gaps and provide clinicians with robust data to inform treatment decisions.The systematic literature review was funded by Takeda Development Center Americas, Inc
Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis
Get PDFGlial fibrillary acidic protein; Intrathecal IgM synthesis; Multiple sclerosisProteïna àcida fibril·lar glial; Síntesi intratecal d'IgM; Esclerosi múltipleProteína ácida fibrilar glial; Síntesis intratecal de IgM; Esclerosis múltipleThe combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB–positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB–negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.This study was funded by the Instituto de Salud Carlos III (ISCIII) through project PI21/00828 and PI24/01018, by grant RD21/0002/0053 from La Red Española de Enfermedades Inflamatorias (REI), and by grants RD24/0007/0013, RD24/0007/0034, RD16/0015/0001, RD16/0015/0002, RD16/0015/0003, and RD16/0015/0006 from La Red Española de Esclerosis Múltiple (REEM). The study also received additional support from the European Union
Full informatiu del Sistema d’Informació per a la Vigilància d’Infeccions a Catalunya – 2025/11
Get PDFVigilància d'infeccions; Epidemiologia; Assistència sanitàriaInfection surveillance; Epidemiology; Health careVigilancia de infecciones; Epidemiología; Asistencia sanitariaL’objectiu de l’informe de la xarxa Sistema d’Informació per a la Vigilància d’Infeccions a Catalunya (SIVIC) és tenir un sistema de vigilància creat per seguir no només els casos més greus sinó també els casos comunitaris de diverses infeccions respiratòries, com són Covid-19, grip, virus sincitial respiratori i enterovirus, entre d’altres
El VIH i les hepatitis són infeccions que tenen tractament: fes-te les proves! [cartell]
Get PDFInfeccions; VIH; Hepatitis; ProvesInfecciones; VIH; Hepatitis; PruebasInfections; HIV; Hepatitis; TestsAquest cartell informa que tant el VIH com les hepatitis tenen un tractament específic i anima a la ciutadania a fer-se les proves.This poster informs that both HIV and hepatitis have specific treatment and encourages citizens to get tested.Este cartel informa que tanto el VIH como las hepatitis tienen un tratamiento específico y anima a la ciudadanía a realizar las pruebas
Anàlisi de la sensibilitat als antimicrobians de Staphylococcus aureus causant de la malaltia invasiva: Catalunya 2020-2024
Get PDFResistència als antimicrobians; Infeccions; Staphylococcus aureusAntimicrobial resistance; Infections; Staphylococcus aureusResistencia a los antimicrobianos; Infecciones; Staphylococcus aureusL’objectiu d’aquest Informe és l’anàlisi de la sensibilitat als antibiòtics de S. aureus SASM i de S. aureus SARM invasius, aïllats a Catalunya en el període 2020 – 2024.El objetivo de este Informe es el análisis de la sensibilidad a los antibióticos de S. aureus SASM y de S. aureus SARM invasivos, aislados en Cataluña en el periodo 2020 – 2024.The objective of this Report is to analyze the susceptibility to antibiotics of invasive S. aureus SASM and S. aureus MRSA, isolated in Catalonia in the period 2020 – 2024
Acsa brief - 2025, 03-maig-juny
No full textAliments; Riscos emergents; Seguretat alimentàriaFood; Food safety; Food risk assessmentAlimentos; Riesgos emergentes; Seguridad alimentariaEl perclorat i el clorat.El perclorato y el clorato
Urgències relacionades amb el consum de drogues: informe d’activitat assistencial - 2024
No full textUrgències hospitalàries; Consum de drogues; Consum d'alcoholHospital emergencies; Drug use; Alcohol consumptionUrgencias hospitalarias; Consumo de drogas; Consumo de alcoholEn aquest document es presenten les dades de les urgències hospitalàries de Catalunya notificades durant l’any 2022 pels hospitals en el registre del conjunt mínim bàsic de dades d’urgències (CMBD-UR), al qual s’ha de notificar tota l’activitat d’atenció urgent del sistema sanitari integral d’utilització pública de Catalunya (SISCAT). A continuació es mostren les dades de les urgències hospitalàries ateses relacionades amb les drogues, en el cas de les persones de dotze anys o més en funció del tipus d’urgència i les urgències atribuïbles al consum d’alcohol en funció del grup d’edat i del sexe
Circuit territorial d’agilització del diagnòstic i protecció davant maltractaments a persones grans: AIS Nord
Get PDFDiagnòstic i protecció; Maltractaments; Persones gransDiagnóstico y protección; Maltrato; Personas mayoresDiagnosis and protection; Abuse; Elderly peopleAquest document descriu un circuit àgil i consensuat en el marc del Comitè Operatiu Treball Social Sanitari (COTTSS) de l'AIS Nord de Barcelona, format per les treballadores socials sanitàries (TSS) de les diferents línies assistencials de salut del territori, per tal de millorar la resposta assistencial davant situacions de maltractament i/o negligència a persones de 65 anys o més amb sospita de deteriorament cognitiu. Es tracta d'una actuació dissenyada per reduir esperes, garantir diagnòstics precoços i activar mesures de protecció adequades.Este documento describe un circuito ágil y consensuado en el marco del Comité Operativo de Trabajo Social Sanitario (COTTSS) del AIS Norte de Barcelona, formado por las trabajadoras sociales sanitarias (TSS) de las diferentes líneas asistenciales de salud del territorio, con el fin de mejorar la respuesta asistencial ante situaciones de maltrato y/o negligencia hacia personas de 65 años o más con sospecha de deterioro cognitivo. Se trata de una actuación diseñada para reducir esperas, garantizar diagnósticos precoces y activar medidas de protección adecuadas.This document describes an agile and agreed-upon procedure within the framework of the Social Healthcare Work Operational Committee (COTTSS) of the Northern Barcelona Integrated Health Area (AIS Nord), made up of healthcare social workers (TSS) from the different healthcare service lines in the area. Its purpose is to improve the care response in situations of abuse and/or neglect of people aged 65 or older with suspected cognitive impairment. The procedure is designed to reduce waiting times, ensure early diagnoses, and activate appropriate protection measures
Exercici columna lumbar [fullet]
No full textSalut; Exercicis; Columna lumbarSalud; Ejercicios; Columna lumbarHealth; Exercices; Lumbar spineInfografies que presenten diversos exercicis per afavorir un estil de vida saludable. Els exercicis se centren en la columna lumbar i abasten des del nivell inicial fins l'avançat.Infografías que presentan diversos ejercicios para favorecer un estilo de vida saludable. Los ejercicios se centran en la columna lumbar y abarcan desde el nivel inicial hasta el avanzado.Infographics presenting various exercises to promote a healthy lifestyle. The exercises focus on the lumbar spine and range from beginner to advanced level
Single-Agent Divarasib in Patients With KRAS G12C–Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Get PDFOral inhibitor; Non-small cell lung cancerInhibidor oral; Càncer de pulmó de cèl·lules no petitesInhibidor oral; Cáncer de pulmón de células no pequeñasDivarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C-positive non-small cell lung cancer (NSCLC). Here, we report long-term (≥1 year) follow-up of single-agent divarasib from the ongoing, open-label, and multicenter phase I study (ClinicalTrials.gov identifier: NCT04449874). The primary objective was safety, and the other objectives included preliminary antitumor activity. Overall, 65 patients with advanced KRAS G12C-positive NSCLC received single-agent oral divarasib 50-400 mg once daily and 31 patients (48%) were treated beyond 1 year. Divarasib continued to be well tolerated, and the safety profile beyond 1 year was consistent with the overall safety profile. In patients with measurable disease at baseline across all dose levels (n = 63), the confirmed objective response rate was 55.6% (95% CI, 42.5 to 68.1), and the median duration of response was 18.0 months (95% CI, 11.1 to 24.9). The median progression-free survival was 13.8 months (95% CI, 9.8 to 25.4) in the overall population (N = 65) and 15.3 months (95% CI, 12.3 to 26.1) among patients assigned to the 400-mg dose level (n = 44). With extended follow-up, divarasib demonstrated long-term safety and antitumor activity in patients with advanced KRAS G12C-positive NSCLC.Supported by Genentech, Inc